Dr. Kratzke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
424 Harvard St Se
Masonic Cancer Center, First Floor, Suite M100
Minneapolis, MN 55455Phone+1 612-625-5411- Is this information wrong?
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1983 - 1986
- University of Washington School of MedicineClass of 1983
Certifications & Licensure
- MN State Medical License 1998 - 2025
- WI State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers Start of enrollment: 2008 Dec 01
- Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 Start of enrollment: 2005 Nov 01
Publications & Presentations
PubMed
- 3 citationsNonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade.Aditya Jain, Shijia Zhang, Ryan M Shanley, Naomi Fujioka, Robert A Kratzke
Cancer Immunology, Immunotherapy. 2023-05-01 - 162 citationsA single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein bindingFrederic J. Kaye, Robert A. Kratzke, Jean L. Gerster, Jonathan M. Horowitz
Proceedings of the National Academy of Sciences of the United States of America. 1990-09-01 - 80 citationsPoor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.Jonathan D'Cunha, James E. Herndon, Debra L. Herzan, G. Alexander Patterson, Leslie J. Kohman
Lung Cancer. 2005-05-01
Journal Articles
- LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry Based Biomarkers in Resected Non-Small Cell Lung CancerRobert Kratzke, MD, Clinical Lung Cancer
Press Mentions
- OncLive® Presents State of the Science Summit™ on Lung CancerAugust 1st, 2019
- Masonic Cancer Center Professor Elected Chair of the Big Ten Cancer Research Consortium Steering CommitteeDecember 23rd, 2016
Grant Support
- Protocol Review &Monitoring SystemNational Cancer Institute2009–2012
- CDK Inhibitors And Response To DHAC In MesotheliomaNational Cancer Institute2000–2001
Professional Memberships
- Member
Hospital Affiliations
- M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: